Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/55124
DC FieldValueLanguage
dc.contributor.authorValldeoriola, Francescen_US
dc.contributor.authorGrandas, Franciscoen_US
dc.contributor.authorSantos-García, Diegoen_US
dc.contributor.authorRegidor, Ignacioen_US
dc.contributor.authorCatalán, María Joséen_US
dc.contributor.authorArbelo, José Matíasen_US
dc.contributor.authorPuente, Víctoren_US
dc.contributor.authorMir, Pabloen_US
dc.contributor.authorParra, Juan Carlosen_US
dc.date.accessioned2019-02-22T19:16:45Z-
dc.date.available2019-02-22T19:16:45Z-
dc.date.issued2016en_US
dc.identifier.issn1758-2024en_US
dc.identifier.urihttp://hdl.handle.net/10553/55124-
dc.description.abstractAim: To assess long-term effectiveness and tolerability of levodopa–carbidopa intestinal gel (LCIG) in Spanish patients with advanced Parkinson's disease. Patients & methods: This was an observational, multicenter, cross-sectional, retrospective study. Results: Data of 177 patients were analyzed. LCIG treatment led to a reduction in the percentage of daily ‘off’ time (16.2 vs 47.6% before LCIG), an increase in the percentage of daily ‘on’ time without disabling dyskinesia (55.6 vs 21.6%). Most patients experienced improvements in freezing of gait, tremor, dizziness, fatigue or flat mood. Adverse events related to levodopa, gastrostomy and technical issues were reported in 36.2, 42.4 and 43.5% of patients, respectively. Conclusion: This study confirms the long-term effectiveness and safety profile of LCIG in patients with advanced Parkinson's disease.en_US
dc.languageengen_US
dc.relation.ispartofNeurodegenerative disease managementen_US
dc.sourceNeurodegenerative disease management [ISSN 1758-2024], v. 6(4), p. 289-298en_US
dc.subject32 Ciencias médicasen_US
dc.subject.otherDyskinesiaen_US
dc.subject.otherLevodopa–carbidopa intestinal gelen_US
dc.subject.otherNonmotor symptomsen_US
dc.subject.other‘off’ timeen_US
dc.subject.otherParkinson's diseaseen_US
dc.titleLong-term effectiveness of levodopa-carbidopa intestinal gel in 177 Spanish patients with advanced Parkinson's diseaseen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.2217/nmt-2016-0021en_US
dc.identifier.scopus85050579743-
dc.contributor.authorscopusid35396953100-
dc.contributor.authorscopusid7003949790-
dc.contributor.authorscopusid55891769300-
dc.contributor.authorscopusid7801463554-
dc.contributor.authorscopusid7006398036-
dc.contributor.authorscopusid26655226900-
dc.contributor.authorscopusid8363845600-
dc.contributor.authorscopusid14060780400-
dc.contributor.authorscopusid57198218953-
dc.description.lastpage298en_US
dc.description.firstpage289en_US
dc.relation.volume6en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.utils.revisionNoen_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr0,452
dc.description.sjrqQ3
dc.description.esciESCI
item.fulltextSin texto completo-
item.grantfulltextnone-
crisitem.author.fullNameArbelo González, José Matías-
Appears in Collections:Artículos
Show simple item record

SCOPUSTM   
Citations

24
checked on Jul 21, 2024

WEB OF SCIENCETM
Citations

23
checked on Jul 21, 2024

Page view(s)

70
checked on Mar 16, 2024

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.